Urokinase is a novel serine proteases found in all tissues and organs. It has the ability to generate fibrillar proteins necessary for tissue repair and can be synthesized by human or animal skin. The human urokinase gene was first discovered, but not named, by McFarlane and Pilling at 1947. Since that time, many other enzymes have been added to the family of urokinase enzymes. Most recently, the molecular biology expert Dr. Michael J. Zick, discovered urokinase in human plasma and liver, demonstrating the profound effect it has on DNA repair and DNA maintenance.
Market Dynamics
High prevalence of pulmonary embolism is expected to propel growth of the urokinase market. For instance, according to the study, ‘Prevalence of Pulmonary Embolism in Patients With Syncope’, published in Journal of the American College of Cardiology, in August 2019, the incidence of new PEs or cardiovascular death during 2-year follow-up was 0.9%. In the subgroup of patients hospitalized (47%), PE was detected at presentation in 15 patients. Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.
High incidence of obesity is expected to offer lucrative growth opportunities for players in the urokinase market. For instance, according to the Centers of Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2018, 71424.3 thousand people in the U.S. suffer from obesity.
Urokinase is contraindicated in patients suffering from cancer, brain tumor, and high blood pressure, which is expected to hinder growth of urokinase market.
Among regions, North America is expected to witness significant growth in the urokinase market, owing to high prevalence of cardiovascular diseases. For instance, according to the American Heart Association's Heart and Stroke Statistics 2019 Update, around 48% of all adults in the U.S. suffered from some type of CVD in 2016.
Competitive Analysis
Major players operating in the urokinase market include, Jiangsu Aidea Pharmaceutical Co Ltd, Jiangxi Haoran Bio-Pharma Co., Ltd, Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, Microbix Biosystems Inc, Syner Medica LTD, ImaRx Therapeutics, Inc, Monopar Therapeutics, and Wilex AG.
Major players operating in the urokinase market are focused on R&D to expand their product portfolio. For instance, in December 2020, Monopar Therapeutics and NorthStar Medical Radioisotopes, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic (uPRIT) for severe COVID-19, selected an uPRIT clinical candidate.
In-depth Report on Urokinase Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/ongoing-insight/urokinase-market-4151
No comments:
Post a Comment